Figure 8.
The assessment of immunotherapy response between the two risk groups. (A) Comparisons of the 44 ICGs in the two risk groups. (B) Comparisons of the proportions of non-responders and responders to ICIs between the two risk groups. (C) Differences in risk score between the responders and non-responders. (D–G) Differences in the IPS between the two risk groups stratified by CTLA4 and PD-1. (H) The proportion of patients with response to anti-PD-1/L1 immunotherapy in patients with high or low risk score in IMvigor210 cohort. (I) Survival analyses for patients with high or low risk score in IMvigor210 cohort. (J) The proportion of patients with response to anti-PD-1/L1 immunotherapy in patients with high or low risk score in GSE78220 cohort. (K) Survival analyses for patients with high or low risk score in GSE78220 cohort. Statistical significance at the level of ns>0.05, *≤0.05, **≤0.01, ***≤0.001 and ****≤0.0001.